TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Ketamine and Propofol Combination Versus Propofol for Upper Gastrointestinal Endoscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* BMI \> 30~* Undergoing an upper gastrointestinal endoscopy~Exclusion Criteria:~* History of schizophrenia/schizoaffective disorder~* History of bipolar disorder~* History of dementia~* Non-English Speaking~* History of Glaucoma~* Craniofacial Abnormalities~* Epilepsy~* Allergy to Propofol~* Allergy to Ketamine~* Current known intracranial mass/lesion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Ketofol and Propofol (Type: EXPERIMENTAL): This arm receives a 50mg dose of Ketamine mixed with 100mg of Propofol at the start of their upper endoscopy.
- Propofol only (Type: ACTIVE_COMPARATOR): This arm receives 100mg of Propofol mixed with 1mL of saline at the start of the upper gastrointestinal endoscopy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Patients With Bulky GIST Using Sunitinib

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients more than 19 years old with pathologically proven GIST which is bulky or marginally resectable~* Patients must have at least one bidimensionally measurable disease site of 5 cm or greater not previously irradiated. Bone lesions do not qualify.~* Patients must have an ECOG performance of greater than or equal to 2, with projected survival of at least three months.~* Patients must have adequate laboratory parameters:~Hematologic: Hb \>9.0; WBC \>3200 and platelets \>100,000/mm3; Hepatic: Bilirubin \<2.0 and AST within 4 times upper limit of normal; Renal: Creatinine of less than or equal to 1.6 or eGFR greater than or equal to 50 mL/min~* Men and women who are of childbearing potential must practice strict birth control for the duration of the study.~* Women of childbearing potential must be non-lactating and non-pregnant with a negative pregnancy test within two weeks of trial registration.~* The patient, a witness, and attending physician will have signed an IRB-approved informed consent prior to Sunitinib administration.~Exclusion Criteria:~* Known brain metastases or significant pleural effusion or ascites.~* Uncontrolled hypertension, diabetes, or other medical condition.~* Major surgery within 21 days of registration.~* Patients wtih organ grafts with the exception of prior high dose chemotherapy with autologous bone marrow (or stem cell) transplantation.~* History of seizures, central nervous system disorders, dementia, or psychosis that might preclude adequate informed consent or protocol compliance.~* Prior therapy for GIST.~* A history of HIV or hepatitis virus infection.~* Any recent medical condition which, in the opinion of the investigator, makes the patient unsuitable for study participation.~* Patients with impaired kidney function.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sunitinib pill (Type: EXPERIMENTAL): Patients will receive six weeks of sunitinib and then subsequently continue for an additional 6 weeks if the evaluation at 6 weeks shows stable disease or objective response. Restaging CT scans will be performed again after 12 weeks of therapy to determine response in preparation for surgical resection anticipated to occur around week 14-16.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Acupuncture or Medication in Reducing Pain in Postmenopausal Women With Breast Cancer and Joint Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of breast cancer~* Concurrent therapy with anastrozole for the adjuvant treatment of breast cancer~* Must have moderate or worse arthralgia, as defined by a baseline WOMAC pain scale score ≥ 48~  * Patients with other underlying pain syndromes (e.g., osteoarthritis) are eligible, but the arthralgia must have worsened since starting anastrozole~* Hormone receptor-positive disease~PATIENT CHARACTERISTICS:~* Post-menopausal status meeting the following criteria:~  * At least 12 months without spontaneous menstrual bleeding~ * History of bilateral salpingo-oophorectomy with or without hysterectomy~ * Age \> 55 with hysterectomy with or without oophorectomy~ * Age \< 55 with hysterectomy without oophorectomy or with unknown status, and serum FSH in post-menopausal range within the past 4 weeks~* Not needle phobic~* Patients with a contraindication to NSAIDs (i.e., prior gastrointestinal bleed secondary to NSAIDs or severe renal insufficiency) are eligible, but will be treated with alternative analgesics such as narcotics or acetaminophen~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* Concurrent chronic narcotics or NSAIDs allowed, but doses must be stable for ≥ the past month~* Concurrent antidepressant medications allowed, but doses must be stable for ≥ the past 3 months~* At least 6 months since prior acupuncture~* No prior acupuncture for aromatase inhibitor-associated pain syndrome

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): Patients undergo acupuncture for 20-30 minutes, on the appropriate pain points on the anterior portion of the body alternating with posterior portion of the body, thrice weekly for 2 weeks and then twice weekly for 3 weeks.
- Arm II (Type: ACTIVE_COMPARATOR): Patients receive standard-of-care analgesics (i.e., NSAIDs, narcotics, acetaminophen, or other) for 5 weeks. Patients not responding to analgesia may cross over to arm I.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Episodic Future Thinking and Future Thinking Priming for Smoking Cessation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Smoke \>= 8 cigarettes daily~* Planning to quit in the next 14 days~* No regular use of other tobacco products~* Access to the internet~* In possession of a smartphone with text messaging capabilities~* In possession of an email address accessible at least every other day~Exclusion Criteria:~* Unable or unwilling to provide consent~* Unable to provide data to the research team after the quit date~* Current use of bupropion or varenicline~* Drinking \>= 20 alcoholic drinks per week~* Use of drugs of abuse in the past 30 days~* Living in the same household as a participant already enrolled in this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Arm I (active EFT, active FTP) (Type: EXPERIMENTAL): Participants are provided with Forever Free relapse prevention booklets and receive a 2-week supply of nicotine patches, gum, or lozenges. Participants also receive 1 proactive coaching call within 24 hours of quit date. Beginning on the quit date, participants complete an active episodic future thinking or active future thinking priming task once per week for 12 weeks, alternating every week between tasks.
- Arm II (active EFT, control FTP) (Type: EXPERIMENTAL): Participants are provided with Forever Free relapse prevention booklets and receive a 2-week supply of nicotine patches, gum, or lozenges. Participants also receive 1 proactive coaching call within 24 hours of quit date. Beginning on the quit date, participants complete an active episodic future thinking or control future thinking priming task once per week for 12 weeks, alternating every week between tasks.
- Arm III (control EFT, active FTP) (Type: EXPERIMENTAL): Participants are provided with Forever Free relapse prevention booklets and receive a 2-week supply of nicotine patches, gum, or lozenges. Participants also receive 1 proactive coaching call within 24 hours of quit date. Beginning on the quit date, participants complete a control episodic future thinking or active future thinking priming task once per week for 12 weeks, alternating every week between tasks.
- Arm IV (control EFT, control TFP) (Type: ACTIVE_COMPARATOR): Participants are provided with Forever Free relapse prevention booklets and receive a 2-week supply of nicotine patches, gum, or lozenges. Participants also receive 1 proactive coaching call within 24 hours of quit date. Beginning on the quit date, participants complete a control episodic future thinking or control future thinking priming tasks once per week for 12 weeks, alternating every week between tasks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Immunostimulating Interstitial Laser Thermotherapy in Solid Cancers

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Are male or female \> 18 years of age~* Have histologically confirmed, locally uncontrolled, solid cancer, with or without metastases, that cannot be treated surgically due to unresectability or inoperability~* Have one or more tumours assessable by MRI/CT or ultrasound and situated in such a way that at least a part of the tumour can be treated with IMILT without damage to surrounding vital structures or the skin~* Are candidates for ablative intervention also outside this study~* Have given informed verbal and written consent to participation in the trial~* Have an ECOG performance status \< 2 (Karnofsky \> 60%)~* Have stable haematologic, renal and hepatic functions~Exclusion Criteria:~* Are HIV positive~* Have an active autoimmune disease~* Are on systemic corticosteroid medication (local treatment with aerosol's and ointment is allowed)~* Have known bleeding disorders or are treated with anticoagulant medication~* Are pregnant or nursing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- imILT (Type: EXPERIMENTAL): Immunostimulating Interstitial Laser Thermotherapy (imILT)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness and Safety of Korean Medicine for Lumbar Stenosis Patients With Sciatica

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with radiating leg pain with or without low back pain (LBP) (walking pain NRS ≥4)~* Patients with dural sac cross-sectional area (DSCA) of \<100 mm2 or morphological grading ≥B as assessed on MRI~* Patients with clear neurogenic claudication symptoms (symptoms aggravated with walking, and alleviated upon resting in lumbar flexion position)~* Patients who have received surgery recommendation for lumbar spinal stenosis~* Patients with plans of receiving Korean medicine treatment for lumbar spinal stenosis for ≥2 months~* Patients who have agreed to study participation~Exclusion Criteria:~* Patients with vascular claudication~* Patients with other systemic diseases that may interfere with treatment effect or outcome interpretation~* Patients with soft tissue pathologies or pathologies of non-spinal origin that may cause LBP or radiating leg pain (e.g. spinal tumor, rheumatoid arthritis)~* Patients for whom acupuncture treatment may be inappropriate or unsafe (e.g. hemorrhagic diseases, blood clotting disorders, history of anti-coagulation medicine intake, serious diabetes with risk of infection, severe cardiovascular diseases, or other conditions deemed unsuitable for acupuncture treatment)~* Pregnant patients or patients planning pregnancy~* Patients with serious psychological disorders~* Patients unable to fill out study participation consent form~* Subjects deemed unsuitable for study participation as assessed by the researchers

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Lumbar stenosis group (Type: None): Lumbar stenosis patients will be administered integrative Korean medicine treatment consisting of herbal medicine, Chuna manipulation, bee venom pharmacopuncture and pharmacopuncture, acupuncture, electroacupuncture, cupping, and other interventions, as needed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Antineoplaston Therapy in Treating Patients With Stage IV Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed stage IV melanoma that is recurrent or progressing and unlikely to respond to existing therapy~* Measurable disease by MRI or CT scan~  * Tumor must be at least 2 cm in the lymph nodes in the head, neck, axillary, inguinal, or femoral areas and at least 0.5 cm in other locations~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* Karnofsky 60-100%~Life expectancy:~* At least 2 months~Hematopoietic:~* WBC at least 2,000/mm3~* Platelet count at least 50,000/mm3~Hepatic:~* Bilirubin no greater than 2.5 mg/dL~* SGOT and SGPT no greater than 5 times the upper limit of normal~* No hepatic insufficiency~Renal:~* Creatinine no greater than 2.5 mg/dL~* No renal insufficiency~* No renal conditions that contraindicate high dosages of sodium~Cardiovascular:~* No chronic heart failure~* No uncontrolled hypertension~* No history of congestive heart failure~* No other cardiovascular conditions that contraindicate high dosages of sodium~Pulmonary:~* No severe lung disease, such as chronic obstructive pulmonary disease~Other:~* Not pregnant or nursing~* Fertile patients must use effective contraception during and for 4 weeks after study~* No serious medical or psychiatric disorders~* No active infection~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* At least 4 weeks since prior immunotherapy and recovered~* No concurrent immunomodulating agents~Chemotherapy:~* At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered~* No concurrent antineoplastic agents~Endocrine therapy:~* Concurrent corticosteroids allowed~Radiotherapy:~* At least 8 weeks since prior radiotherapy and recovered (patients with multiple tumors who have received radiotherapy to some, but not all, tumors may be admitted earlier than 8 weeks)~Surgery:~* Recovered from prior surgery~Other:~* Prior cytodifferentiating agent allowed~* No prior antineoplaston therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Antineoplaston therapy (Type: EXPERIMENTAL): Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Boron Neutron Capture Therapy Using Boronophenylalanine-Fructose Complex in Treating Patients With Metastatic Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed melanoma~  * Metastatic disease~    * Brain metastases, skin metastases, or soft tissue metastases of the head and neck or the extremities~ * Accessible lesion(s) for boron neutron capture therapy (BNCT)~ * No clear progression of disease at other sites than the ones intended for treatment with surgery and/or BNCT~* Measurable disease by MRI within the past 4 weeks~  * Lesion(s) ≥ 10 mm in diameter~* Indication for palliative radiotherapy that is intended to be delivered as BNCT~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* Karnofsky 70-100%~Life expectancy~* Not specified~Hematopoietic~* Neutrophil count ≥ 2,000/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Hemoglobin ≥ 10 g/dL~Hepatic~* Bilirubin ≤ 2.5 times upper limit of normal (ULN)\*~* Transaminases ≤ 2.5 times ULN\*~* Alkaline phosphatase ≤ 2.5 times ULN\* NOTE: \*Unless due to reversible reaction to antiseizure medication~Renal~* Creatinine ≤ 2.5 times ULN~* Blood urea nitrogen ≤ 2.5 times ULN~Cardiovascular~* No congestive heart failure~* No newly diagnosed or unstable angina pectoris~* No uncontrolled arrhythmias~* No uncontrolled conduction defects~* No recent coronary artery disease~* No other severe heart disease~Pulmonary~* No severe pulmonary disease, including severe obstructive or restrictive lung disease~Other~* No history of phenylketonuria~* No severe gastrointestinal disease~* No active peptic ulcer disease~* No uncontrolled endocrine disease~* No pre-existing serious mental or organic brain disease (e.g., epilepsy)~* No psychological, familial, sociological, or geographical condition that would preclude study compliance~* Able to travel to the Netherlands via public transportation~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy~* No concurrent immunologic or biologic therapy~* No concurrent colony-stimulating factors (e.g., epoetin alfa or filgrastim \[G-CSF\])~Chemotherapy~* No concurrent chemotherapy~Endocrine therapy~* No concurrent hormonal therapy~Radiotherapy~* No prior radiotherapy to site(s) proposed for study treatment~* No other concurrent radiotherapy~Surgery~* See Disease Characteristics~Other~* Recovered from all prior anti-tumor therapy (excluding alopecia and sensitive peripheral neuropathy ≤ grade 2)~* No other concurrent anticancer therapy~* No other concurrent investigational drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have histologically documented AML, ALL, MDS, CML, Acute myeloid leukemia (AML) with one or more of the following criteria~  * CR 1 with poor risk features~ * CR 2, or higher order CR~* Acute lymphoblastic leukemia (ALL) with one of the following criteria~  * CR 1 with poor risk features~ * CR 2, or higher order CR~* Myelodysplasia, RAEB I~* Donor has been identified~* Age ≤ 65 years.~* Performance Status 0-1.~Exclusion Criteria:~* Patients relapsing \<6 months after autologous SCT are not eligible.~* Patients with active infections requiring oral or intravenous antibiotics are not eligible for enrollment until resolution of infection.~* Non-pregnant and non-nursing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Total body Irradiation; Thiotepa; Fludarabine; Rabbit ATG;
- 2 (Type: EXPERIMENTAL): Palifermin; Total Body Irradiation; Thiotepa; Fludarabine; Rabbit ATG

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Preliminary Efficacy and Tolerability of NCX-1000 After Repeated Oral Doses in Patients With Elevated Portal Pressure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or non-pregnant female patients of at least 18 years old~* HVPG \> 12 mm Hg in fasting state on Day 1~* Free of any other condition (except liver failure) that may alter absorption, distribution, or elimination of drugs~Exclusion Criteria:~* Oesophageal bleeding in the previous 30 days~* Known intolerance to ursodeoxycholic acid or nitrates~* Liver cancer or liver metastasis from another cancer~* Portal hypertension secondary to venous thrombosis~* Presence of Transjugular Intrahepatic Portosystemic Shunt (TIPS)~* Severe liver failure (Child-Pugh C)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NCX-1000 (Type: EXPERIMENTAL): Experimental drug under evaluation
- Placebo (Type: PLACEBO_COMPARATOR): Placebo powder

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy